How are ApoB and Wechseljahre related?

ApoB is a core protein of atherogenic lipoproteins (LDL, VLDL) and is considered a more precise marker of cardiovascular risk than LDL cholesterol alone. Menopause (Wechseljahre) involves a sharp decline in estrogen, which alters lipid metabolism: LDL cholesterol and ApoB levels typically rise, while HDL cholesterol often decreases. This shift contributes to the increased cardiovascular risk observed in postmenopausal women. However, the provided context does not include direct evidence—such as clinical trials or genetic studies—linking ApoB specifically to menopause. The relationship is therefore based on established physiological mechanisms rather than context-specific data. A MyBody-X test might measure ApoB as a biomarker, but interpretation requires clinical context and consideration of other risk factors. Caveat: single biomarkers or genetic variants (e.g., in the APOB gene) have limited predictive power without integrating lifestyle, diet, and overall health status. Evidence is mechanistic, not from the given context.